Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit, BioMerieux Call off Colon Cancer Collaboration

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics and BioMerieux are discontinuing their collaboration aimed at identifying biomarkers and developing tests for colon cancer, ExonHit announced today.

The decision reportedly comes on the heels of a recent review of scientific and clinical data from the colon cancer screening research program.

However, the companies plan to continue working together to find biomarkers and develop tests for early-stage prostate cancer.

"ExonHit's technology was able to produce a robust and reproducible test however, the final results from the colon cancer program did not reach the level of performance we were aiming to achieve," Loic Maurel, president of ExonHit's management board, said in a statement. "Therefore, we have decided together with BioMerieux to focus our efforts on the prostate cancer program."

As reported by GenomeWeb Daily News sister publication BioArray News reported last month, ExonHit is also developing microarray-based test for Alzheimer's disease that it hopes to launch in Europe early next year and in the US sometime in 2012.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.